• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

    2.170 +0.140 (+6.90%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,155,169
    Open 2.050
    Bid (Size) 2.130 (100)
    Ask (Size) 2.170 (100)
    Prev. Close 2.030
    Today's Range 2.050 - 2.210
    52wk Range 1.040 - 4.460
    Shares Outstanding 142,183,418
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Allogene (ALLO) Q2 2026 Earnings Call Transcript ↗
    Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Allogene Therapeutics Q2 Earnings Call Highlights ↗
    Allogene Therapeutics (NASDAQ:ALLO) outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +60.7%
    +60.7%
    1 Month
    +24.0%
    +24.0%
    3 Month
    +2.4%
    +2.4%
    6 Month
    +4.3%
    +4.3%
    1 Year
    +87.1%
    +87.1%

    More News

    Read More
    News headline image
    Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces Planned CEO Succession
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Allogene (ALLO) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Allogene Therapeutics Q1 2026 Earnings Call Transcript ↗
    Via Benzinga
    Topics Earnings
    News headline image
    Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are making the most noise in today's session. ↗
    Via Chartmill
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
    Via AB Newswire
    News headline image
    Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗
    Via Benzinga
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
    Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
    The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
    What is the current price of Allogene Therapeutics, Inc. - Common Stock?
    The current price of Allogene Therapeutics, Inc. - Common Stock is 2.170
    When was Allogene Therapeutics, Inc. - Common Stock last traded?
    The last trade of Allogene Therapeutics, Inc. - Common Stock was at 08/25/26 04:00 PM ET
    What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
    The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 308.54M
    How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
    Allogene Therapeutics, Inc. - Common Stock has 309M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.